ABG Sundal Collier acted as Sole Global Coordinator in Ascelia Pharma’s fully subscribed rights issue of units of SEK 105 million

On Thursday 5 September 2024, Ascelia Pharma announced the successful completion of the fully subscribed rights issue of units of SEK 105 million. The proceeds raised will, among other things, enable Ascelia Pharma to complete the filing of the New Drug Application (NDA) to the Food & Drug Administration (FDA) for Orviglance by mid-2025 as well as conducting partnering activities ahead of Orviglance commercialization.
In addition to the initially raised SEK 105 million, one series of warrants were issued as part of the rights issue of units, which may yield additional gross proceeds totalling SEK 21 – 70 million if subscribed for in full in April 2025.